DongKoo Bio & Pharma

동구바이오제약 · 006620

Health Care Pharmaceuticals · KOSDAQ

Small-cap

Market cap US$86.6M (₩119.6B)

Overview

DongKoo Bio & Pharma makes and supplies pharmaceutical products, medicines used in everyday medical treatment, to the Korean healthcare market.

It is listed on KOSDAQ, South Korea's technology and small-cap stock exchange. The filing's table of contents covers a broad range of products and services, research and development activity, and production facilities, suggesting the company operates across multiple pharmaceutical product lines rather than a single narrow focus.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$175.9M

▼ −2.6% YoY

Operating profit · FY2025

US$6.7M

▼ −27.1% YoY

Net income · FY2025

US$36.4M

▲ +2420.3% YoY

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$156.3M(₩215.7B)	US$180.6M(₩249.3B)	US$175.9M(₩242.7B)
Operating profit	US$10.6M(₩14.6B)	US$9.2M(₩12.7B)	US$6.7M(₩9.2B)
Net income	US$8.6M(₩11.8B)	US$1.4M(₩2B)	US$36.4M(₩50.2B)

Revenue

FY2023US$156.3M
FY2024US$180.6M
FY2025US$175.9M

Operating profit

FY2023US$10.6M
FY2024US$9.2M
FY2025US$6.7M

Net income

FY2023US$8.6M
FY2024US$1.4M
FY2025US$36.4M

Key ratios (FY2025)

ROE

33.0%

Debt/Eq

121.0%

Op. margin

3.8%

Net margin

20.7%

Rev. YoY

▼ −2.6%

Price charts coming soon

Interactive price history isn't here yet. Would you use it?